Insys Therapeutics (INSY), the once high-flying drug maker that is among the companies blamed for fueling the U.S. opioid crisis, is in danger of going out of business.

A combination of financial losses and uncertainty about its cash position prompted its auditor to determine there is “substantial doubt” whether the company can continue “as a going concern,” according to documents filed with the Securities and Exchange Commission. The drug maker added that it is trying to raise funds, but conceded there are “no assurances” (see page 43).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Excellent closing line – “The current Insys management has otherwise kept busy trying to develop cannabinoid products.” As I was reading, I wondered ‘what they were smoking’ to engage in such activities.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy